{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3TC+and+FTC", "query": { "intervention": "3TC and FTC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 65, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3TC+and+FTC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T17:43:10.412Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00949234", "title": "Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Prevention", "HIV Infections" ], "interventions": [ { "name": "tenofovir + emtricitabine, lopinavir/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2010-03", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2017-12-18", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949234" }, { "nct_id": "NCT00152061", "title": "The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "3TC and FTC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2005-01", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 1, "location_summary": "San Jose, California", "locations": [ { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00152061" }, { "nct_id": "NCT01363011", "title": "Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2011-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-05-02", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363011" }, { "nct_id": "NCT04302896", "title": "Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Medication Adherence", "HIV" ], "interventions": [ { "name": "dolutegravir oral tablet 50mg", "type": "DRUG" }, { "name": "emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg", "type": "DRUG" }, { "name": "tenofovir disoproxil fumarate oral tablet 300mg", "type": "DRUG" }, { "name": "lamivudine oral tablet 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhonda Brand", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-08-31", "completion_date": "2021-09-30", "has_results": false, "last_update_posted_date": "2022-03-03", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302896" }, { "nct_id": "NCT00039741", "title": "Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)", "type": "DRUG" }, { "name": "NNRTIs (EFV, NVP)", "type": "DRUG" }, { "name": "PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": "18 Years", "sex": "ALL", "summary": "30 Days to 18 Years" }, "enrollment_count": 266, "start_date": "2002-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 29, "location_summary": "Alhambra, California • Long Beach, California • Los Angeles, California + 22 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039741" }, { "nct_id": "NCT00737568", "title": "Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "TDF Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 280, "start_date": "2008-09", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 3, "location_summary": "Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Bradenton", "state": "Florida" }, { "city": "Flushing", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00737568" }, { "nct_id": "NCT00102206", "title": "A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 6, "start_date": null, "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 4, "location_summary": "Chicago, Illinois • New York, New York • Stony Brook, New York + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00102206" }, { "nct_id": "NCT00112047", "title": "Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Emtricitabine (FTC)", "type": "DRUG" }, { "name": "Tenofovir Disoproxil Fumarate (TDF)", "type": "DRUG" }, { "name": "Efavirenz (EFV)", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "FTC/TDF/EFV", "type": "DRUG" }, { "name": "Lamivudine/zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 517, "start_date": "2003-07", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2010-10-13", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 5, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112047" }, { "nct_id": "NCT00951015", "title": "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK1349572", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2009-07-30", "completion_date": "2016-12-22", "has_results": true, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Bakersfield, California • Long Beach, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00951015" }, { "nct_id": "NCT02924389", "title": "Dolutegravir in Reservoirs", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "dolutegravir", "type": "DRUG" }, { "name": "Triumeq", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2016-09", "completion_date": "2019-09-11", "has_results": true, "last_update_posted_date": "2022-12-29", "last_synced_at": "2026-09-02T17:43:10.412Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924389" } ] }